Abeona Therapeutics (ABEO) Free Cash Flow (2011 - 2026)

Abeona Therapeutics' Free Cash Flow history runs 16 years deep, the most recent figure standing at -$20.7 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 4.73% year-over-year to -$20.7 million; the TTM figure through Mar 2026 stood at -$85.2 million (down 35.29% YoY), while the FY2025 annual figure was -$84.3 million, down 44.2% from the prior year.
• Free Cash Flow was -$20.7 million for Q1 2026 at Abeona Therapeutics, down from -$19.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$5.8 million in Q3 2023 to a low of -$23.7 million in Q3 2025.
• Historically, Free Cash Flow has averaged -$14.4 million across 5 years, with a median of -$13.8 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow soared 58.16% in 2022, then tumbled 118.27% in 2024.
• A 5-year view of Free Cash Flow shows it stood at -$14.0 million in 2022, then surged by 33.85% to -$9.3 million in 2023, then slumped by 85.13% to -$17.2 million in 2024, then decreased by 11.31% to -$19.1 million in 2025, then decreased by 8.55% to -$20.7 million in 2026.
• The last three Free Cash Flow figures came in at -$20.7 million (Q1 2026), -$19.1 million (Q4 2025), and -$23.7 million (Q3 2025), per Business Quant data.